The Covered Business Methods Program Must Finally Be Laid to Rest

By James Edwards
August 10, 2020

“The Covered Business Methods program should expire of disinterest, if not to eliminate a proceeding of questionable use, of illegitimate vintage, and of unjust intent.” – Group letter to Senators Tillis and Coons

https://depositphotos.com/6528683/stock-photo-rose-on-a-grave.htmlRather than allowing it a quiet death, the financial services industry is making a quiet effort to keep the Covered Business Methods (CBM) Program at the Patent Trial and Appeal Board (PTAB) alive.

The special interest group has reportedly enlisted Senator Richard Blumenthal (D-CT) to push for an extension of the CBM program for one year. A rider on the next COVID supplemental appropriations package, or possibly a FY 2021 Commerce Department appropriations bill, would carry the grant of CBM’s stay of expiration.

A Political Fix That Should Not Be Prolonged

CBM is one of three administrative adjudicatory proceedings at the PTAB. The 2011 America Invents Act created the PTAB and its tripartite means of administratively pursuing invalidation of issued patents, for the first time denying patent owners de novo review by and the superiority of Article III federal courts. Inter partes review is the most-used proceeding at the PTAB, while post grant proceedings are second-most used.

Referred to in the AIA as a “transitional” program, CBM is scheduled to expire permanently on September 16, 2020. The program was created as a political fix for ulterior purposes directly benefitting the financial services industry.

Plenty of opposition to extending CBM’s life exists. CBM was roundly decried during the AIA debate. Its opponents — many then and more now — include inventors, entrepreneurs, intellectual property organizations such as the Licensing Executives Society (USA & Canada) and the Small Business Technology Council, conservative and free-market organizations, and innovative business groups, including the Innovation Alliance, the National Small Business Association and U.S. Business & Industry Council.

[[Advertisement]]

Bipartisan Opposition

In 2015, then-Congressman Darrell Issa (R-CA), who chaired the House Judiciary IP Subcommittee at the time, proposed an amendment in committee to extend CBM. A bipartisan majority voted down the Issa CBM amendment. This, despite the amendment’s support by full Judiciary Committee Chairman Robert Goodlatte (R-VA).

As then-Ranking Member John Conyers (D-MI) pointed out in leading the opposition, the USPTO had expanded CBM’s reach beyond financial services business methods. He said this exceeding of its statutory limitations made CBM “a new tool for infringers to drain legitimate patent holders of resources.”

Among the nonfinancial services business method patents challenged in CBM proceedings are personalized nutrition information, digital rights management and pharmaceuticals, IEEE-USA notes.

Further, Congressman Conyers said the AIA designated the CBM program as “transitional” to deal with a specific set of supposedly “weak” patents.

Three months after the Issa amendment’s defeat, the USPTO recommended abiding by CBM’s scheduled date for its discontinuation.

The banking sector’s hubris showed in its seeking to lengthen CBM’s life just three years after it was created. Yet even having political friends in charge of the Judiciary Committee and IP Subcommittee couldn’t get the bankers their political fix by then. And the infringer-friendly Obama USPTO called for CBM’s scheduled demise in 2020.

CBM’S Time is Up

The 11th-hour attempt to sneak a CBM extension into big, moving legislation weeks before CBM’s death date has been anticipated. Organizations, in addition to those named above, have written Senate Judiciary IP Subcommittee Chairman Thom Tillis (R-NC) and Ranking Member Chris Coons (D-DE) asking that CBM expire as scheduled. Signatories of the letter include the Alliance of U.S. Startups & Inventors for Jobs, Conservatives for Property Rights, Logicpatents LLC, the Market Institute and U.S. Inventor.

“CBM should expire of disinterest, if not to eliminate a proceeding of questionable use, of illegitimate vintage, and of unjust intent,” the group letter says. The letter discusses diminishing petitions for CBM proceedings; its broad expansion beyond the original intent of financial services-related business methods to all useful arts; the driving purpose behind CBM being to deliver the special interest a political favor that would invalidate the oft-infringed and oft-affirmed patents of independent inventor Claudio Ballard, to whom the banks had to pay royalties and licensing fees; and the cronyism and targeted political guarantee of patent invalidation, overruling administratively what Article III courts had consistently found valid and infringed and due damages.

Other correspondence to Senate IP leaders came from IEEE-USA. This engineering professional organization details CBM’s breadth of issues that may be considered, its technological areas now subject to review in this proceeding, the ostensible rationale for a “transitional” program and congressional and USPTO support for its termination, and CBM usage “declining to insignificant levels.”

IEEE-USA also raises concerns about CBM’s adverse effects on emerging technologies, including its harm to business and investment related to commercialization:

Protections for technologies from artificial intelligence to DRM [digital rights management] to blockchain or to cybersecurity — which are implemented through software — are put at greater risk because of the CBM Program. This risk reduces the incentives for research and development investment due to a perception that the patents protecting the exclusive rights obtained by such investment can be more easily challenged and invalidated than patents in other areas.

Eagle Forum Education & Legal Defense Fund wrote the Senators, addressing ways in which CBM “remain[s} problematic from constitutional, legal, and policy perspectives.”  Eagle Forum Education discusses separation of powers issues, effects on the rule of law and international IP implications.

On whether and how CBM abrogates the constitutional separation of powers, this correspondence notes administrative-state-related problems with CBM. The AIA brought judicial powers into an administrative body, whose “judges” are unconstitutionally appointed. Yet, AIA empowers CBM and PTAB’s administrative functionaries to overrule Senate-confirmed federal judges’ rulings on the same patents.

This means CBM diminishes the rule of law by “destabilizing res judicata,” Eagle Forum Education writes. The PTAB proceeding renders all court-decided issues pertinent to a given patent unsettled. Parties may continue to raise the same issues and rechallenge the same patents on the same grounds a federal court has already decided. Further, owners of administratively invalidated patents receive no compensation due pursuant to the Takings Clause.

Eagle Forum Education notes how CBM may abrogate the Trade-Related Aspects of Intellectual Property, or TRIPS, agreement. By treating business-method patents differently from other species of patentable subject matter, CBM not only likely violates TRIPS, it also invites China and other foreign competitors not to honor international IP protections.

Stay Proactive to Ensure CBM Dies

The financial services sector’s chances of success in winning a reprieve of its pet PTAB program were better by flying under the radar of the front-page news controversies involving the next COVID-related supplemental appropriations package and FY21 appropriations. But that path is precluded.

For invention, patent reliability and the future of computer-enabled business processes, the outcome of this CBM tug-of-war carries consequences. With patent owners and inventors proactive on this matter, they may just win, CBM expire, and one product of political cronyism laid to rest.

Image Source: Deposit Photos
Author: jlueders
Image ID: 6528683

The Author

James Edwards

James Edwards consults on intellectual property, health care innovation, and regulatory and policy issues. Edwards advises companies, trade associations, and conservative organizations on patent policy and is Co-Director of the Inventor's Project. He participates in the Medical Device Manufacturers Association's Patent Working Group. Edwards mentors start-ups and early-stage companies, largely in the med tech space, and is involved in several IP-centric projects.

Edwards served as Legislative Director to Rep. Ed Bryant, R-Tenn., then a member of the U.S. House Judiciary Committee, and handled IP legislative matters. Edwards also worked on the staffs of Rep. John Duncan, R-Tenn., the U.S. Senate Judiciary Committee, and Sen. Strom Thurmond, R-S.C. In addition, he was an association executive at the Healthcare Leadership Council. Edwards earned a Ph.D. at the University of Tennessee, and bachelor's and master's degrees at the University of Georgia.

Warning & Disclaimer: The pages, articles and comments on IPWatchdog.com do not constitute legal advice, nor do they create any attorney-client relationship. The articles published express the personal opinion and views of the author as of the time of publication and should not be attributed to the author’s employer, clients or the sponsors of IPWatchdog.com. Read more.

Discuss this

There are currently 2 Comments comments. Join the discussion.

  1. Pro Say August 11, 2020 8:23 pm

    CBMs?

    Good riddance.

    R.I. P.

  2. blockchain training in hyderabad October 28, 2020 8:18 am

    your article on blockchain is very interesting thank you so much.

Post a Comment

Respectfully add to the discussion.

Name *
Email *
Website